The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | TA |
| ID number | 3975 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 March 2024 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 05 October 2022 | As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course. |
| 03 August 2022 - 01 September 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 03 August 2022 | In progress. Scoping commenced |
| 31 March 2022 | As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma after a BTK inhibitor. Please note that the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2022. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 24 November 2021 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual